Regen BioPharma Inc (RGBP)

[cvinvestor]

If you go back to PRs relating to Feb 2013 IND for HemaXellerate, the PRs state that first they need FDA approval for clinical trials and then they would submit Orphan Drug status within 30 days of approval. Since aplastic-anemia has already been designated as a condition that qualifies for orphan drug status, filing and obtaining that status for HemaXellerate will only be a formality once it is approved to proceed with clinical trials.

Again, I am not saying they haven't. What I am asking is why this is not public knowledge if they have. That's something material that us investors should know about. Don't you think? And investor1 thinks it is or he knows it has been submitted? Two different things.